Sympathetic activation in congestive heart failure: an updated overview

Area of Science:

• Cardiology
• Neuroscience
• Physiology

Background:

• Sympathetic nervous system (SNS) activation is a significant hallmark in congestive heart failure (CHF).
• This activation is an early phenomenon, correlating with disease severity and exacerbated by comorbidities like obesity, diabetes, and hypertension.
• Adrenergic overdrive in CHF leads to detrimental cardiovascular effects.

Purpose of the Study:

• To review the evidence linking sympathetic nervous system activation to congestive heart failure.
• To explore the consequences of adrenergic overdrive on the cardiovascular system.
• To discuss neuromodulatory therapeutic interventions targeting sympathetic activation in heart failure.

Main Methods:

• Review of biochemical, neurophysiological, and neuroimaging studies on human sympathetic neural function.
• Analysis of the relationship between sympathetic activation, comorbidities, and cardiovascular consequences.
• Examination of therapeutic strategies targeting the sympathetic nervous system in heart failure.

Main Results:

• Sympathetic activation is consistently observed in heart failure patients and is linked to disease severity.
• Adrenergic overdrive contributes to endothelial dysfunction, left ventricular hypertrophy, atherosclerosis, arrhythmias, and myocardial necrosis.
• A strong correlation exists between sympathetic activation and mortality in heart failure.

Conclusions:

• Sympathetic nervous system overactivity is a critical factor in the pathophysiology and progression of congestive heart failure.
• Neuromodulatory therapies targeting adrenergic overdrive represent a promising therapeutic avenue.
• Further research is needed for specific interventions like renal denervation and baroreceptor stimulation.